{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T22:05:49Z","timestamp":1784930749257,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.breast.2026.104795","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T22:55:15Z","timestamp":1777762515000},"page":"104795","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients"],"prefix":"10.1016","volume":"88","author":[{"given":"Sandra","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pfarrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie M.","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Pasalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Jeryczynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Marhold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerwin","family":"Heller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2591-1380","authenticated-orcid":false,"given":"Jutta","family":"Bergler-Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Spannbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten","family":"Fuereder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6095-4899","authenticated-orcid":false,"given":"Filippo","family":"Cacioppo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Laggner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Preusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4384-6917","authenticated-orcid":false,"given":"Rupert","family":"Bartsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5455-9139","authenticated-orcid":false,"given":"Christoph","family":"Minichsdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6797","key":"10.1016\/j.breast.2026.104795_bib1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.breast.2026.104795_bib2","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1158\/1055-9965.EPI-12-0474","article-title":"Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades","volume":"21","author":"Haque","year":"2012","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.breast.2026.104795_bib3","article-title":"Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers","volume":"2014","author":"Parise","year":"2014","journal-title":"J Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.breast.2026.104795_bib4","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1158\/1055-9965.EPI-17-0627","article-title":"Differences in breast cancer survival by molecular subtypes in the United States","volume":"27","author":"Howlader","year":"2018","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"21","key":"10.1016\/j.breast.2026.104795_bib5","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina breast cancer study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2026.104795_bib6","doi-asserted-by":"crossref","first-page":"5329","DOI":"10.2147\/CMAR.S176763","article-title":"Breast cancer subtypes and the risk of distant metastasis at initial diagnosis: a population-based study","volume":"10","author":"Xiao","year":"2018","journal-title":"Cancer Manag Res"},{"issue":"20","key":"10.1016\/j.breast.2026.104795_bib7","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104795_bib8","article-title":"Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study","volume":"7","author":"Gong","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.breast.2026.104795_bib9","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00432-018-2644-2","article-title":"Patterns of breast cancer relapse in accordance to biological subtype","volume":"144","author":"Ignatov","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104795_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen international expert Consensus on the primary therapy of early breast cancer 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.breast.2026.104795_bib11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.breast.2026.104795_bib12","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"issue":"10075","key":"10.1016\/j.breast.2026.104795_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","article-title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin adjuvant (HERA) trial","volume":"389","author":"Cameron","year":"2017","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.breast.2026.104795_bib14","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1056\/NEJMoa1413513","article-title":"Pertuzumab, trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer","volume":"372","author":"Swain","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.breast.2026.104795_bib15","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","article-title":"Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies","volume":"188","author":"Dempsey","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"10.1016\/j.breast.2026.104795_bib16","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2450","article-title":"Trends in adult cancer-related emergency department utilization: an analysis of data from the nationwide emergency department sample","volume":"3","author":"Rivera","year":"2017","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.breast.2026.104795_bib17","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women with early breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.breast.2026.104795_bib18","article-title":"Trends and characteristics of potentially preventable emergency department visits among patients with cancer in the US","volume":"6","author":"Alishahi","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.breast.2026.104795_bib19","series-title":"Surveillance research program","article-title":"An interactive website for SEER cancer statistics [internet]","year":"2024"},{"issue":"15 Pt 1","key":"10.1016\/j.breast.2026.104795_bib20","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.breast.2026.104795_bib21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10549-022-06721-1","article-title":"Reproductive history differs by molecular subtypes of breast cancer among women aged \u2264 50 years in Scotland diagnosed 2009\u20132016: a cross-sectional study","volume":"196","author":"Chitkara","year":"2022","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.breast.2026.104795_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju055","article-title":"US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status","volume":"106","author":"Howlader","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"10.1016\/j.breast.2026.104795_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3679","article-title":"Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes","volume":"16","author":"Maisonneuve","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104795_bib24","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s12094-014-1220-8","article-title":"Differential patterns of recurrence and specific survival between luminal A and luminal B breast cancer according to recent changes in the 2013 St Gallen immunohistochemical classification","volume":"17","author":"Garc\u00eda Fern\u00e1ndez","year":"2015","journal-title":"Clin Transl Oncol"},{"issue":"25","key":"10.1016\/j.breast.2026.104795_bib25","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1200\/JCO.2013.54.1870","article-title":"Luminal B breast cancer: molecular characterization, clinical management, and future perspectives","volume":"32","author":"Ades","year":"2014","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.breast.2026.104795_bib26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"10.1016\/j.breast.2026.104795_bib27","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.breast.2026.104795_bib28","doi-asserted-by":"crossref","first-page":"E734","DOI":"10.9778\/cmajo.20170030","article-title":"Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data","volume":"5","author":"Fallahpour","year":"2017","journal-title":"CMAJ Open"},{"issue":"19","key":"10.1016\/j.breast.2026.104795_bib29","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"10.1016\/j.breast.2026.104795_bib30","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/1078-0432.CCR-16-1278","article-title":"High-risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant cyclophosphamide-based chemotherapy: results from the DBCG77B clinical trial","volume":"23","author":"Nielsen","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.breast.2026.104795_bib31","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.breast.2026.104795_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000073","article-title":"Twenty years of anti-HER2 therapy-associated cardiotoxicity","volume":"1","author":"Pond\u00e9","year":"2016","journal-title":"ESMO Open"},{"issue":"41","key":"10.1016\/j.breast.2026.104795_bib33","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.breast.2026.104795_bib34","series-title":"Herceptin (trastuzumab) [prescribing information]","year":"2024"},{"issue":"5","key":"10.1016\/j.breast.2026.104795_bib35","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.3390\/cancers13051015","article-title":"The exciting new field of HER2-Low breast cancer treatment","volume":"13","author":"Eiger","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.breast.2026.104795_bib36","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-Low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001050?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626001050?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T21:31:06Z","timestamp":1784928666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626001050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":36,"alternative-id":["S0960977626001050"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104795","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2-directed therapy is associated with an increased rate of cardiologic emergency department visits in real-world breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104795","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104795"}}